Cargando…
Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON)
The Dermatologic Oncology Group of Japan Clinical Oncology Group has started a randomized phase III trial to confirm the superiority of adjuvant therapy with locoregional interferon beta in overall survival over surgery alone for patients with pathological stage II/III cutaneous melanoma (JCOG1309)....
Autores principales: | Namikawa, Kenjiro, Tsutsumida, Arata, Mizutani, Tomonori, Shibata, Taro, Takenouchi, Tatsuya, Yoshikawa, Shusuke, Kiyohara, Yoshio, Uchi, Hiroshi, Furue, Masutaka, Ogata, Dai, Tsuchida, Tetsuya, Yamazaki, Naoya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896686/ https://www.ncbi.nlm.nih.gov/pubmed/29136453 http://dx.doi.org/10.1093/jjco/hyx063 |
Ejemplares similares
-
A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol)
por: Oashi, Kohei, et al.
Publicado: (2020) -
Confirmatory trial of non-amputative digit preservation surgery for subungual melanoma: Japan Clinical Oncology Group study (JCOG1602, J-NAIL study protocol)
por: Tanaka, Kiyo, et al.
Publicado: (2019) -
Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation‐positive advanced cutaneous melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2018) -
Genomic landscape and its prognostic significance in stage III colorectal cancer: JCOG1506A1, an ancillary of JCOG0910
por: Shida, Dai, et al.
Publicado: (2023) -
Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy‐naive advanced melanoma
por: Namikawa, Kenjiro, et al.
Publicado: (2020)